Keyword: Xtandi


7. Sanofi

Sanofi had a bit of a year to forget when it came to buying up biotechs and expanding its pipeline—it failed to beat out Pfizer in its winning $14 billion bid for cancer biotech Medivation, losing out on some increasingly hot cancer candidates and blockbuster prostate cancer med Xtandi.
Office lobby

4. Pfizer

For many years, Pfizer was hit by waves of criticism for its failure to develop new blockbusters to replace the big drugs that had bulked up its revenue. Those critics wanted to see more outsourcing, more partnerships and smaller in-house research empires. Pfizer has in many ways steered toward that course, and 2016 saw more evidence of this.